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ABSTRACT 
The landscape of HPV infection in racial/ethnic subgroups of head and neck cancer 
(HNC) patients has not been evaluated carefully. In this study, a meta-analysis examined 
the prevalence of HPV in HNC patients of African ancestry. Additionally, a pooled analysis 
of subject-level data was also performed to investigate HPV prevalence and patterns of 
p16 (CDNK2A) expression amongst different racial groups. Eighteen publications (N = 
798 Black HNC patients) were examined in the meta-analysis, and the pooled analysis 
included 29 datasets comprised of 3,129 HNC patients of diverse racial/ethnic 
background. The meta-analysis revealed that the prevalence of HPV16 was higher 
among Blacks with oropharyngeal cancer than Blacks with non-oropharyngeal cancer. 
However, there was great heterogeneity observed among studies (Q test P<0.0001). In 
the pooled analysis, after adjusting for each study, year of diagnosis, age, gender and 
smoking status, the prevalence of HPV16/18 in oropharyngeal cancer patients was 
highest in Whites (61.1%), followed by 58.0% in Blacks and 25.2% in Asians (P<0.0001). 
There was no statistically significant difference in HPV16/18 prevalence in non-
oropharyngeal cancer by race (P=0.682). With regard to the pattern of HPV16/18 status 
and p16 expression, White patients had the highest proportion of HPV16/18+/p16+ 
oropharyngeal cancer (52.3%), while Asians and Blacks had significantly lower 
proportions (23.0% and 22.6%, respectively) [P <0.0001]. Our findings suggest that the 
pattern of HPV16/18 status and p16 expression in oropharyngeal cancer that appears to 
differ by race and this may contribute to survival disparities by race. 
 
 
Introduction 
 
Head and neck cancer (HNC) is the sixth most common cancer in the world, 
accounting for approximately 4% of all cancer cases (1). In 2012, there were an estimated 
599,637 new cases of cancer of the oral cavity, larynx and oropharynx, and 324,794 
deaths attributed to the disease worldwide(1). Although tobacco and alcohol use are the 
primary risk factors for developing HNC, human papillomavirus (HPV) is also an 
established risk factor for cancers arising in the oropharynx (2;3). Recently, HPV has also 
been reported to be associated with a subset of oral cavity cancers (4;5), but an etiological 
role has not been clearly demonstrated.   
A recent review and meta-analysis from our group of head and neck cancer 
survival in relation to HPV demonstrated a survival advantage for all HPV-positive 
patients (6), but the survival advantage was only significant for patients with cancer of the 
oropharynx. Compared to patients with HPV-negative oropharyngeal cancer, the risk of 
death and risk of recurrence for patients with HPV-positive oropharyngeal cancer was 
reduced by ~28% and ~49%, respectively. In the United States (US), a clear disparity in 
HNC survival has been reported between Black and White patients, particularly for 
oropharyngeal cancers. Poor survival rates for Black Americans compared to White 
Americans have been observed (7), and some studies have suggested that this disparity 
may be explained at least partially by a difference in prevalence of HPV infection (8-10). 
Comparisons of HPV prevalence in cancer of the oral cavity and larynx between various 
racial/ethnic populations have been reported in a recent meta-analysis (11). However, a 
summary of HPV prevalence for Black patients was only reported for oral cavity cancer 
in this study (11). Furthermore, an assessment of attributed survival differences for 
oropharyngeal cancer between racial/ethnic populations was not conducted. 
The goal of the present study was to develop a more complete perspective of the 
landscape of HPV infection in ethnic subgroups of head and neck cancer patients by 
examining the published literature. We conducted a meta-analysis examining the 
prevalence of HPV in the Black population. We also performed a pooled analysis of cases 
reporting HNC and HPV status using subject-level data from the published literature to 
investigate HPV segregation and prevalence amongst different ethnic groups. 
 
Materials and methods 
This study was approved by the Fox Chase Cancer Center Institutional Review 
Committee.   
Literature review and data collection 
A PubMed search was conducted (from inception to December 2014) using the 
search terms, ("human papillomavirus"[All Fields] OR "HPV"[All Fields]) AND ("squamous 
cell carcinoma"[All Fields] OR "cancer"[All Fields]) AND ("oropharyngeal"[All Fields] OR 
"oropharynx"[All Fields] OR "head and neck"[All Fields] OR "tonsil"[All Fields]). All 
abstracts and full text of articles from the PubMed search were reviewed independently 
by two reviewers. When there was a discrepancy between reviewers, a third reviewer 
evaluated the article(s) to resolve the discrepancy. All studies that tested for the presence 
of HPV in head and neck cancer tissues from patients diagnosed with squamous cell 
carcinoma of the head and neck (oral cavity, oropharynx, larynx and hypopharynx) were 
eligible for inclusion in this analysis. The bibliographies of several review articles were 
also examined in order to identify additional publications that might have been missed by 
our PubMed search (11-15). This review identified 291 original articles that qualified 
conditionally for the analysis. Studies that used serology methods to detect HPV 
antibodies were excluded from the analysis, as this method does not identify which tissue 
is infected by HPV. Studies that primarily evaluated HPV in lip cancers were excluded 
from this analysis, with the exception of studies where it was impossible to distinguish lip 
cancer data from the other head and neck subsites. In addition, case reports and studies 
that included only HPV-positive head and neck cancer tumors/patients were excluded. 
Additional exclusion criteria includes studies of HNC patients who were co-infected with 
other diseases, such as HIV; studies in which the cancer tissues were sampled via cyto-
brushing and not biopsy or surgery; studies that classified HNC as HPV-related or HPV 
non-related tumors based on tumor site without directly testing that tissue for HPV; 
studies in which fewer than 80% of the eligible cases were tested for HPV; and studies 
that selected patient samples non-randomly, but applied pre-defined criteria for patient 
inclusion (e.g., patients with undifferentiated carcinoma only, metastasis only, positive 
lymph nodes only, advanced stage only, patients who underwent a specific treatment 
regimen, studies where smoking and drinking patient tissues were matched with 
nonsmoker and nondrinker patient tissues, etc.). For overlapping studies, the publication 
with the largest population and/or more complete information was included in this 
analysis. After accounting for these inclusion and exclusion criteria, 140 articles with data 
for all racial/ethnic populations were eligible for inclusion in this study. Of these, only 18 
articles presented data that could be abstracted and were included in the meta-analysis 
of Black cancer patients. All 140 articles were eligible for inclusion in the pooled analysis. 
A flow diagram of study selection is illustrated in Figure 1. 
Meta-analysis of Black HNC patients. From each of the 18 articles that included data from 
Black HNC patients (818 cases), information on the number of patients, HPV prevalence, 
HPV genotype, tumor subsite, mean age, year of cancer diagnosis, geographic location 
of the study, tissue source, HPV test methodology and HPV-infected cancer site were 
extracted and tabulated. All data were abstracted independently by two reviewers and 
cross-referenced to confirm that there were no data entry errors. Three studies that 
included data for fewer than 10 Black patients (16-18) were therefore excluded from the 
meta-analysis, leaving 15 studies including 798 cases.  
Pooled analysis. All investigators from the 140 studies were invited to submit their subject-
level data for this pooled analysis; data from 22 studies were obtained. The remaining 
study investigators either did not respond or did not wish to participate. Common data 
elements included in the pooled analysis were HPV test method, HPV status, HPV 
genotype, DNA source, geographic location of the study, age at diagnosis, gender, 
race/ethnicity, p16 status, tobacco and alcohol use, clinical variables (such as tumor site, 
histology and stage) and survival variables (such as vital status and follow-up time). 
Seven additional articles reported demographic, clinical, HPV results, tobacco, alcohol 
and survival data in the publications, which enabled us to create pseudo-datasets for 
inclusion in the pooled analysis. All patients included in this analysis were diagnosed with 
cancers of the oral cavity, oropharynx, or larynx. Patients with hypopharyngeal cancers 
were grouped with the patients with cancers of the larynx. Patients with metastases or 
unknown primaries were excluded from this analysis. In total, there were 29 datasets 
including a total of 3,129 head and neck cancer cases.  
Statistical Analysis 
The Meta-proportion of any HPV and HPV16 only was calculated for all HNC subsites 
combined as well as separately for oropharynx and non-oropharynx data. All statistical 
analyses were performed using Intercooled STATA SE (version 10) software (StataCorp. 
LP, College Station, TX). Meta-analyses of the proportion of HPV-positive HNC were 
performed using the metaprop command in STATA. HPV proportions were calculated for 
each individual study and the reported confidence intervals were based on Clopper-
Pearson exact binomial procedures(19). Pooled proportions of the multiple studies were 
estimated using a random effects model. The Meta-prevalence estimates were calculated 
by multiplying the Meta-proportion and confidence interval values by 100. The Q-statistics 
were used to test for heterogeneity between the studies included in the meta-analyses. 
The I2 metric was also calculated to quantify variation between studies (20). Large 
between-study variation was observed when the I2 values were ≥50% while moderate 
between-study heterogeneity was denoted by I2 values between 25-50%. Evidence of 
publication bias or small study effects (p<0.05) was assessed using the Egger’s test (21).  
 
For the pooled analysis, unequal variance in age was observed between 
categories of race. Therefore, a square root transformation of age at diagnosis was 
performed. Adjusted HPV prevalence and 95% confidence intervals for each racial/ethnic 
group was calculated from logistic regression estimates for HPV-positive status, adjusting 
for study, year of diagnosis, square root of age, sex, history of alcohol drinking, and 
smoking history. The adjusted prevalence refers to the average HPV prevalence while 
averaging the values of the covariates in the regression model. The logistic coefficients 
and standard errors are provided in Supplementary Materials. A Likelihood Ratio chi-
square test was performed to evaluate differences between the adjusted prevalence 
according to race and an analysis of variance (ANOVA) was used to compare the mean 
square root of age at diagnosis between racial groups (p-values for pairwise comparisons 
were Bonferroni adjusted). P-values < 0.05 were considered statistically significant. Mean 
age at diagnosis for each stratum was back transformed and reported. Follow-up time for 
overall survival refers to the interval between date of diagnosis and the date of last contact 
(if the patient was alive) or date of death. Hazard ratios (HR) were calculated and adjusted 
for each study and other confounders for risk of death or risk of disease progression (i.e., 
disease persistence, recurrence and/or metastasis). HR<1.0 represents an overall 
survival benefit and HR>1.0 represents poor overall survival.  
 
Results 
 
Meta-analysis, description of studies 
 Table 1 summarizes all published studies from which data were available to 
estimate HPV (any HPV or HPV16) prevalence in Black populations. Study size ranged 
from 13 to 161 patients. The majority (13/15, 87%) of studies included Polymerase Chain 
Reaction (PCR)-based methods to test for the presence of HPV DNA. For all site strata 
(all head and neck, oropharynx and non-oropharynx), large heterogeneity was observed 
between the studies (Q test p-value range from 0.000-0.048; I2 values range from 62.1%-
94.6%). Nevertheless, as expected, the prevalence of any HPV or HPV16 was higher 
among oropharyngeal cancer patients (any HPV: 31.5%, 95% CI = 17.7-47.1; HPV16: 
45.7%, 95% CI = 25.5-66.6) in comparison to non-oropharyngeal cancer patients (any 
HPV: 14.5%, 95% CI = 1.4-36.0; HPV16: 1.1%, 95% CI = 0.0-6.0). There was no evidence 
of publication bias or small study effect. The reasons for underlying heterogeneity were 
explored by stratifying the dataset according to geographic region (Sub-Saharan Africa 
vs. US) as well as HPV test methods (ISH vs. PCR/RT-PCR). Large heterogeneity 
remained when stratified by HPV test method (data not shown). When stratified by 
geographic region (see Supplementary Table 1), large heterogeneity was still observed 
except when data were limited to HPV16 infections only. For all head and neck subsites 
combined, the meta-prevalence of HPV16 in patients from Sub-Saharan Africa (N = 4 
studies) was 1.0% (95% CI = 0.0-3.9), Q test p-value was 0.129, I2 was 47.0%. Large 
heterogeneity was still observed between the remaining eight studies that included 
patients from the US (Q test P <0.0001, I2 = 89%). Further stratification of the Sub-
Saharan Africa studies according to head and neck subsite resulted in a meta-prevalence 
of HPV16 in non-oropharyngeal cancers at 0.1% (95% CI = 0.0-1.8, Q test p-value = 
0.768, I2 = 0.0%). The only study in the US that reported HPV16 data for non-
oropharyngeal cancer showed a higher prevalence (13.6%, 95% CI = 1.9-31.7) than that 
of patients in Sub-Saharan Africa. There were no studies in Sub-Saharan Africa that 
reported data for HPV16 in oropharyngeal cancer patients and the large heterogeneity 
remained for the US studies that reported HPV16 data in Black oropharyngeal cancer 
patients.   
Pooled analysis, description of studies  
There were a total of 3,129 patients included in this analysis (Table 2).  Variations 
among the 29 studies were noted with regard to study size, the geographic region where 
the study was conducted, tumor site, and the tissue source. Studies varied in size from 
15 to 489 patients and were conducted mostly in Europe (48%, 14/29 studies), followed 
by the US (31%, 9/29), Asia (17%, 5/29) and a single study in Australia. Most of the 
studies (65%, 19/29) involved patients diagnosed with cancers at both oropharyngeal and 
non-oropharyngeal sites (oral cavity, larynx, hypopharynx and non-oropharyngeal sites 
not otherwise specified). The remaining studies included patients diagnosed with 
oropharyngeal cancers only. Formalin-Fixed Paraffin-Embedded (FFPE) tissues were 
examined in 66% of studies to test for the presence of HPV, rather than Fresh Frozen 
(FF) or Fresh Tissue (FT). All except for four studies used PCR methodology to detect 
HPV DNA, using either consensus or type-specific primers, and of these, five also 
evaluated HPV status using DNA in situ hybridization combined with PCR. Two studies 
detected HPV RNA using only RT-PCR and the other two detected both HPV RNA and 
DNA using RT-PCR and PCR. CDKN2A (p16) expression was evaluated in 16 studies 
using immunohistochemistry. With regard to race/ethnicity, the pooled dataset was 
diverse with patients representing African, African American, Asian and White 
populations. There was one study that included Aboriginal Australian patients. These 
patients were combined with the African and African American patients and classified as 
Black. There were 82 patients classified as other race (for 63 patients race was unknown 
and 19 patients included Pacific Islander, Middle Eastern, Indian, Hispanic or other not 
otherwise specified). These patients were grouped and classified as other race. Follow-
up time was available for 19 studies and ranged from 0.03 to 244.5 months with a mean 
follow-up of 41.7 months and a median follow-up of 30.6 months.   
Prevalence of HPV16 and HPV18 according to race and head and neck subsite 
 The prevalence of HPV16 and/or HPV18 (HPV16,18) stratified by race was 
calculated for all head and neck cancers, oropharyngeal cancers only and non-
oropharyngeal cancers only after adjusting for study, year of diagnosis, age, gender, 
alcohol drinking, and smoking status (Table 3, and Supplementary Table 2 which 
summarizes the logistic coefficients and standard errors). As expected, the overall mean 
age for HPV-positive patients diagnosed with oropharyngeal cancers was lower than the 
mean age of HPV-positive patients diagnosed with non-oropharyngeal cancers 
irrespective of whether the patient carried HPV16 or HPV18 in their tumor. The mean age 
at diagnosis was 56.3 years for HPV16,18+ oropharyngeal cancer patients, was 60.1 
years for HPV16,18+ non-oropharyngeal HNC patients (p<0.0001). There was no 
statistically significant difference in the mean age at diagnosis of HPV16,18+ 
oropharyngeal cancer patients according to race. However, for non-oropharyngeal head 
and neck cancer patients, Bonferroni post-hoc test shows that Asians were statistically 
significantly older compared to Whites (HPV16,18: Asians, 64.1 years vs. Whites, 54.9 
years, P = 0.038).  
 As expected, the prevalence of HPV16,18 was higher in oropharyngeal cancer 
tissues compared to non-oropharyngeal cancer tissues (HPV16,18: 48.7% vs. 18.2%). 
HPV16 was the predominant genotype carried in all patient tissues, 46.6% of 
oropharyngeal cancer patients and 13.4% of non-oropharyngeal head and neck cancer 
patients were positive for this genotype. In contrast, only approximately 1-2% of patients 
carried HPV18, irrespective of whether the cancer was diagnosed in the oropharynx or at 
a non-oropharyngeal head and neck site.  
For oropharyngeal cancers, there was a statistically significant difference in the 
prevalence of HPV16,18 according to race. White patients had the highest prevalence of 
HPV16,18+ cancers followed by Blacks then Asians, however, only the prevalence in 
Asian patients was statistically significantly lower (61.1% vs. 58.0% and 25.2%, 
respectively; P <0.0001). A similar pattern was observed for the prevalence of HPV16 
infections. However, for HPV18, Black patients had the highest prevalence (14.8%) 
compared to Asians (1.6%) and Whites (1.1%) and this difference was statistically 
significant (P = 0.0025). For the non-oropharyngeal cancer patients, there was no 
statistically significant difference in HPV16 and/or 18 prevalence according to race.  
Expression of p16 and HPV16,18 DNA according to race in oropharynx cancer patients 
 Twelve studies (1,397 patients) presented with both HPV16,18 and p16 data. 
Among oropharyngeal cancer patients, the pattern of combined HPV16,18 and p16 status 
differed according to race, and this difference was statistically significant (Figure 2A, 
p<0.0001). White patients had the highest proportion of cancers that were 
HPV16,18+/p16+ (52.3%). In contrast, Asian and Black patients had lower proportions of 
tumors with HPV16,18+/p16+ cancers (23.0% and 22.6%, respectively). In addition, Black 
patients had a higher proportion of cancers that were HPV16,18+, but p16- compared to 
Asian and White patients (31.1% vs. 10.5% and 4.7%, respectively). The proportion of 
patients with HPV16,18-/p16- disease also differed significantly by race. Asian patients 
had the highest proportion of HPV16,18-/p16- cancers, in contrast to Black and White 
patients (66.8% vs. 37.7% and 29.6%, respectively).  
 When the oropharyngeal cancer patients were stratified according to smoking 
history, the pattern of combined HPV16,18 and p16 status according to race co-
segregated with the fraction of patients that were ever smokers (Figure 2B). Among never 
smokers (Figure 2C), as expected, patients with HPV16,18+/p16+ cancers comprised the 
predominant fraction among Asian, Black and White patients. However, White patients 
still had the highest proportion, and Asian patients had the lowest (White: 80.1%, Black: 
62.5% Asian: 39.6%, p<0.0001). Even among never smokers, Asians continued to have 
the largest proportion of patients with HPV16,18-/p16- cancers (37.4%), which was 
almost equal to the proportion of HPV16,18+/p16+ cancers (39.6%) observed in this 
subgroup. 
Predictors of overall survival for oropharyngeal cancer patients according to race 
Independent predictors of overall survival for oropharyngeal cancer patients were age at 
diagnosis, smoking history, late stage (III/IV) at diagnosis, and combined HPV16,18 and 
p16 status (Table 4). Patients with HPV16,18-/p16+ cancers had an increased risk of 
death compared to patients with HPV16,18+/p16+ oropharyngeal cancers. There was 
also an even greater increased risk of death for patients with p16- cancers irrespective of 
HPV status. When stratified according to smoking history, among never smokers, 
HPV16,18-/p16- patients were the only group with a statistically significantly increased 
risk of death compared to HPV16,18+/p16+ patients (Hazard Ratio[HR]: 2.70, 95% 
Confidence Interval [CI] 1.12-6.51). Patients with HPV16,18+/p16- or HPV16,18-/p16+ 
oropharyngeal cancers also had an increased risk of death compared to patients with 
HPV16,18+/p16+ oropharyngeal cancers, but the hazard ratios were not statistically 
significant. When stratified according to race, non-White patients differed in comparison 
to White patients regarding risk of death based on HPV16,18/p16 status. Table 4 shows 
that p16 status rather than HPV DNA status appeared to be a predictor of overall survival 
for non-White patients, but not for White patients. For non-Whites, the risk of death was 
statistically significantly increased for patients with p16-negative oropharyngeal cancers, 
irrespective of HPV16,18 status (HPV16,18+/p16-: HR = 2.95, 95% CI = 1.60-5.42, 
HPV16,18-/p16-: HR = 3.11, 95% CI = 1.97-4.92 vs. HPV16,18-/p16+: HR = 0.69, 95% 
CI = 0.24-2.01). In contrast, the risk of death for White patients with p16+ cancers was 
dependent upon HPV16,18 status. White patients with HPV16,18-/p16+ oropharyngeal 
cancers had an increased risk of death (HR = 2.91, 95% CI = 1.72-4.92) in comparison 
to White patients with HPV16,18+/p16+ oropharyngeal cancers.    
The risk of disease persistence, recurrence or metastasis based on HPV16,18/p16 
status differed between White and non-White oropharyngeal cancer patients and is 
presented in Table 5. White patients that did not have HPV16,18+/p16+ disease had an 
increased risk of disease persistence and/or recurrence in comparison to patients 
diagnosed with HPV16,18+/p16+ disease. In contrast non-white patients with HPV16,18-
/p16- were the only subgroup with a greater risk of disease persistence and/or recurrence 
in comparison to HPV16,18+/p16+ disease (HR = 2.70, 95% CI = 1.52-4.82). The risk of 
metastasis was only associated with non-White patients carrying HPV16,18-/p16- 
oropharyngeal cancers.   
 
Discussion  
 
This study expands on our prior reported meta-analysis of HPV and HNC (6). In 
that study, we showed that the presence of HPV infection, specifically in the oropharynx 
had a significant effect on disease-free survival and overall survival. Since the time of that 
publication, HPV-positive squamous cell carcinoma of the oropharynx has been well 
described and reported as a distinct clinical entity. Oropharyngeal cancer patients are 
often non-smokers, male, younger and White compared to traditional substance abuse-
related (tobacco and alcohol) head and neck cancer.  A dramatic increase in 
oropharyngeal cancer prevalence has been identified over the last decade (2;22;23).  The 
number of cases of oropharyngeal cancer exceeded the number of cervical cancer cases 
in 2010 in the United States, and the number of HPV+ oropharyngeal cancer is expected 
to exceed the incidence of cervical cancer by 2020 (2). In addition, the more favorable 
outcome of HPV+ oropharyngeal cancer is well-documented and has been confirmed in 
multiple studies (24;25). These tumors appear to be HPV-related, and a hallmark of 
favorable tumors is p16-positivity. 
 For unclear reasons, the prevalence and favorable outcome of HPV+ 
oropharyngeal cancer is seen mostly in Whites. Variations in the prevalence of HPV have 
been noted previously in studies of Black patients with oropharyngeal cancer, where 
some report lower prevalence and others report a prevalence that is higher and/or 
comparable to White oropharyngeal cancer patients (9;10;26). In the first part of this 
study, the meta-analysis of published HPV prevalence and HNC in Black patients echoes 
these findings. Consistent with what is expected when comparing HPV prevalence in 
oropharyngeal and non-oropharyngeal cancer subsites, we show that for Black patients, 
cancers in the oropharynx have a higher prevalence of HPV16 (45.7%), than non-
oropharyngeal sites (14.5%). There was large heterogeneity between the studies 
included in our meta-analysis. It is possible that differences in the HPV detection methods 
used in different studies may have influenced HPV positivity rates. For example, DNA 
ISH assays lack sensitivity and in general, PCR may lack specificity for transcriptionally 
active virus. Nevertheless, we observed that the meta-prevalence of HPV16 among Black 
patients is similar to the prevalence reported in our pooled analysis (i.e. higher in the 
oropharynx and lower in non-oropharyngeal sites).  
We performed a pooled analysis of published HPV and HNC data in racial/ethnic 
subgroups in order to obtain a broader perspective. HPV status was obtained 
predominantly by PCR on FFPE tissues. Evaluation of HPV16, HPV18, and HPV16,18 
prevalence by subsite and race yielded multiple findings. First, it is clear that HPV, 
specifically HPV16 or HPV18 within the oropharynx is most common in Whites (61%). 
There is a similar yet lower rate of HPV16,18+ disease in Blacks (58%) and a significant 
difference in the rate of HPV16,18+ disease in Asians (25%). This highlights the major 
HPV prevalence difference between Whites and Asians. This finding is curious, since the 
prevalence of HPV in Black patients has been reported to be statistically significantly 
lower than what has been reported for White patients in the literature (22;27). However, 
our pooled analysis reflects data from multiple institutions which is more reliable than a 
single study. The observed differences in HPV prevalence between Asians and Whites is 
also interesting and is not consistent with the previously reported meta-analysis (11). This 
inconsistency might be explained by differences in the type of Asian populations included 
in our study. This pooled analysis only included Asians from Taiwan (China) and Japan 
while the previously published meta-analysis, included Asian populations from China and 
Korea. Significantly higher HPV prevalence was observed in Korean patients compared 
to Chinese patients and could explain the higher prevalence of HPV+ oropharyngeal 
cancer in Asians in that review (11).  
An unexpected finding was the higher prevalence of HPV18 amongst Blacks.  
While HPV18 is rarely reported at either oropharyngeal (1.1%) or non-oropharyngeal 
cancer sites (1.5%) in Whites, HPV18 is nearly fifteen times more frequently detected in 
Black oropharyngeal cancer patients. This major difference was unexpected. It is unclear 
if this is due to a higher rate of HPV18 infection in HNC in Blacks or a lower rate of 
HPV16+ oropharyngeal cancer in Blacks, thereby unmasking HPV18.   
To better characterize oropharyngeal cancers, we evaluated by both HPV and p16 
status. Canonical HPV oropharyngeal cancer is characterized by a HPV+/p16+ signature 
and p16 status has been reported previously as the best prognostic marker for this 
disease (24;28). Oropharyngeal cancer that develops in White nonsmokers is mostly 
likely to be HPV-associated. Our study confirmed this finding; nearly 80% of White 
nonsmokers were HPV+/p16+ (Figure 2C). As p16 loss is associated with smoking (29), 
amongst ever smokers, a much higher incidence of p16- disease was reported in all 
races. Although approximately 45% of ever smokers continue to be HPV+/p16+, only half 
that frequency of HPV+/p16+ is reported in non-Whites. Amongst Blacks and especially 
Asians, HPV-/p16+ disease comprises the majority of oropharyngeal disease, in 
distinction to Whites, where HPV+/p16+ disease is the predominant disease.   
While it is not surprising that patients with HPV-/p16+ oropharyngeal cancer have 
a higher risk of death compared to patients with HPV+/p16+ oropharyngeal cancer, it was 
interesting to note that among non-Whites, the risk of death for patients with HPV-/p16+ 
oropharyngeal cancer was not different from patients diagnosed with HPV+/p16+ 
oropharyngeal cancer (HPV16,18-/p16+ Hazard Ratio: 0.69, 0.24-2.01). Unlike Whites 
(HPV16,18-/p16+ Hazard Ratio: 2.91, 1.72-4.92), the survival benefit among non-Whites 
appears to be attributed to p16 status rather than HPV. In Whites, the survival benefit 
appears to be attributed to HPV status rather than p16 status. However, it is possible that 
HPV16,18-/p16+ oropharyngeal cancers in non-Whites may be attributed to other high-
risk HPV types. Further investigation of the possible role of high-risk HPV types other 
than HPV16,18 in non-White oropharyngeal cancer patients is needed. Overall, our 
findings suggest that the difference in HPV/p16 patterns according to race may impact 
survival differently. Given the multifactorial cause of racial survival disparities, such as 
poor socioeconomic status and poor access to care, the effect of HPV/p16 patterns on 
racial disparities in survival is not easily identified and further investigations are needed.  
A limitation of this study is the use of publications as the source of patient data. 
Unlike database data, like SEER or The National Cancer Database, published data 
represent a sampling of the true population. A major assumption of our pooled analysis 
is that the landscape of the published literature is representative of the population as a 
whole. Given the dramatic differences noted in survival here between Whites and non-
Whites, we feel it is highly unlikely that an error in sampling of the literature can explain 
these differences. A high fraction of cells with expression of p16 in both the nucleus and 
cytoplasm is the only good correlation with prognosis and with high-risk HPV mRNA. For 
each of the studies included in the pooled analysis, we did not have detailed information 
on the cutoffs used to define p16 status (i.e., fraction of p16 expression in nuclei vs. 
cytoplasm). This is also a limitation of our study, as this detail may have provided more 
accurate correlations of p16 expression and outcome according to race.  
The reasons for this difference in patterns of HPV/p16 in oropharyngeal cancer are 
unclear. While smoking status has predicted p16 status (29), even amongst never 
smokers in this study, the prevalence of HPV+/p16+ disease is lower in non-Whites. 
Possible explanations include genetic and environmental causes. The development of 
HPV+ oropharyngeal cancer has been associated with differences in sexual behavior 
patterns and marijuana use (31). Differential sexual and behavior patterns amongst 
Whites vs. non-Whites have not been studied well. While the number of oral sex partners 
has been identified in the risk of developing HPV+ oropharyngeal cancer (31).  The 
percentage difference in ever oral sex partners in individuals 45-60 years old between 
Whites and Blacks appears modest (about 15% difference in prevalence) from a few 
major studies (32;33), but this remains an area of active research. Other potential 
explanations are genetic differences between races and differences in the host response 
to HPV infection, which merit further investigation. Intratypic variation of HPV16 is 
associated with geographical distribution and may contribute to differences in outcome 
(34-39). For example, African and Asian-American intratypic variants of HPV16 show 
higher transforming potential in tumors of the anogenital tract. Therefore, in HNC, 
differential infection by HPV variants between races may also be an important area for 
investigation. 
At this time, we do not have sufficient understanding to offer a clear 
recommendation as to how to reduce oropharyngeal HPV infection or the risk of 
developing HPV+ oropharyngeal cancer. This appears to be a problem of environment 
and biology, without a reversible modifiable factor to reduce risk. We hope that greater 
adoption of HPV vaccination will alter the incidence curve within about 20 years. Our 
study has examined HPV and HNC, with a focus on oropharyngeal cancer. This study 
demonstrates that while HPV-related oropharyngeal cancer (HPV+/p16+) represents the 
majority cause among White patients, Blacks and Asians have lower rates. Because 
HPV-related oropharyngeal cancer has a more favorable outcome regardless of race, the 
differential HPV prevalence amongst Blacks and Asians is expected to cause a significant 
outcome disparity in oropharyngeal cancer treatment. Further studies specifically 
examining racial differences in HPV+ oropharyngeal cancer are needed to corroborate 
these findings. However, this comprehensive pooled analysis of the published literature 
strongly supports a prevalence disparity in HPV+ oropharyngeal cancer that would predict 
an outcome/survival disparity. 
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Table 1: Meta-Analysis of HPV Prevalence in Populations of African Descent 
Study 
HPV test 
Method HPV types detected N 
Any HPV 
N%, 95% CI 
HPV 16  
N%, 95% CI 
ALL HEAD AND NECK  
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Argwal et al. (2008)(43) ISH 16 13 0.0% (0.0-24.7)  0.0% (0.0-24.7) 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Ndiaye C et al. (2013)(50) PCR 16, 35, 45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    798 17% (8.8-27.0) 13.7% (1.5-26.4) 
p value, Q test    0.000 0.000 
I2 test    89.8% 93.8% 
p value, Egger’s test    0.419 0.643 
OROPHARYNX 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013) (49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    146 31.5% (17.7-47.1) 45.7% (25.5-66.6) 
p value, Q test    0.003 0.000 
I2 test    75.5% 84.1% 
p value, Egger’s test    0.997 0.807 
NON-OROPHARYNX 
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 125 24.8% (17.5-33.3)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
Isayeva et al. (2015)(52)* qRT-PCR 16,18 22  13.6% (2.9-34.9) 
TOTAL    337 14.5% (1.4-36.0) 1.1% (0.0-6.0) 
p value, Q test    0.000 0.048 
I2 test    94.6% 62.1% 
p value, Egger’s test    0.685 0.424 
X: HPV genotype unknown; NR: Not reported; *Studies included in the pooled analysis 
Table 2: Description of studies included in the pooled-analysis 
 
*Pseudo datasets created from publication data; FFPE: Formalin-Fixed Paraffin Embedded tissue, FF - Fresh Frozen tissue, FT - Fresh Tissue; PCR - Polymerase Chain 
Reaction, RT-PCR, Real-time PCR (mRNA), HC2 - Hybrid Capture 2, ISH - in situ hybridization, IHC - Immunohistochemistry; A - African, AA - African American, AB - 
Aboriginal Australian, AS - Asian, W - White, UNK - unknown race;  O - Oropharynx, NO - Non-Oropharynx, UNKP - Unknown Primary; FU - Follow-up. 
 
Author (Year) 
Study 
size 
Tissue 
source 
HPV testing 
method 
p16 
expression 
Geographic 
region 
Race/ 
Ethnicity Tumor site 
FU, months 
(median) 
Cruz et al. (1996)(53)* 35 FF PCR -- Europe W NO -- 
Tsuhako et al. (2000)(54)* 88 FFPE PCR -- Asia AS NO , O -- 
Koskinen et al. (2003)(55)* 61 FF PCR -- Europe W NO , O -- 
De Petrini et al. (2006)(56) 70 FF PCR -- Europe W NO, O 30.4 
Ragin et al. (2006)(16) 125 FFPE PCR IHC US W NO, O 48.4 
Armas et al. (2008)(57;58) 280 FFPE PCR IHC Asia AS NO, O 18.6 
Cohen et al. (2008)(59)* 35 FFPE PCR -- US UNK O -- 
Worden et al. (2008)(60) 70 FFPE PCR -- US AA, W NO, O 13.5 
Szarka et al. (2005)(61)  33 FF PCR -- Europe W NO, O 25.4 
Szarka et al.2009(62) 55 FF PCR -- Europe W NO, O 77.4 
Straetmans et al. (2009)(63) 81 FFPE PCR/ISH IHC Europe W O -- 
Tachezy et al. (2009)(64) 135 FFPE PCR -- Europe W NO, O 47.7 
D’Souza et al. (2010)(65) 246 FFPE PCR/ISH -- US AA, AS, W NO, O 31.0 
Eng et al. (2010)(66) 15 FFPE PCR IHC US W NO, O 69.8 
Chernock et al. (2011)(8) 266 FFPE PCR/ISH IHC US AA, AS, W O -- 
Kabeya et al. (2012)(67)* 31 FF PCR IHC Asia AS NO -- 
Hoffman et al. (2012)(68)* 78 FF PCR IHC Europe W NO , O -- 
Park et al. (2012)(69) 89 FFPE PCR IHC Asia AS O 20.9 
Heusinkveld et al. (2012)(70)* 41 FFPE PCR -- Europe W NO, O -- 
Bussu et al. (2013, 2014)(71;72) 136 FT RT-PCR/HC2 IHC Europe A, W NO , O 12.5 
Isayeva et al. (2013; 2015)(52;73) 315 FFPE RT-PCR IHC US AA, AS, W NO, O 27.5 
Deng et al. (2013)(74;75) 131 FF PCR -- Asia AS NO, O 25.1 
Morbini et al. (2013)(76) 52 FFPE PCR/ISH IHC Europe W NO, O 50.5 
Hong et al. (2013)(77) 489 FFPE PCR IHC Australia W, AB, AS O 49.0 
Kruger et al. (2014)(12) 88 FF PCR -- Europe W NO -- 
Liu (2015)(26) 44 FFPE PCR IHC US AA O 18.9 
Morbini et al. (2015)(78) 41 FFPE PCR/ISH IHC Europe W O 21.2 
TOTAL 3,129       30.6 
Table 3: Adjusted prevalence of HPV16 and HPV18 according to race stratified by head and neck sub-site 
 N HPV16+ 
Mean Ageϕ 
(years ± SD) 
HPV16 
Prevalence† 
% (95% CI) 
N HPV18+ 
Mean Ageϕ 
(years, ± SD) 
HPV18 
Prevalence† 
N HPV16,18+ 
Mean Ageϕ 
(years, ± SD) 
HPV16,18 
Prevalence† 
All HNC 
Number of studies = 28 Number of studies = 24 Number of studies =28 
Asian 634 58.9 ± 0.64 28.4% (23.8-33.4) 631 61.9 ± 0.90 1.6% (0.7-3.9) 632 59.0 ± 0.68 26.0% (21.6-30.9) 
Black  158 56.6 ± 0.55 43.7% (34.2-53.8) 85 56.7 ± 0.20 9.8% (4.0-21.9) 131 56.7 ± 0.51 56.2% (45.1-66.7) 
White 2.123 56.5 ± 0.47 36.9% (34.0-40.0) 1,778 54.5 ± 0.50 1.6% (0.9-2.8) 1,915 56.6 ± 0.48 44.0% (40.8-47.3) 
Other* 58 55.3 ± 0.52 34.3% (16.2-58.5) 54 -- 7.7% (1.0-39.6) 58 55.3 ± 0.51 44.9% (23.1-68.8) 
   P=0.0123¥   P = 0.0077¥   P < 0.0001¥ 
TOTAL 2,973 56.8 ± 0.50  35.0% (32.8-37.2) 2,548 58.2 ± 0.70 1.9% (1.2-2.8) 2,736 56.9 ± 0.51 39.3% (37.1-41.7) 
Oropharynx 
Number of studies = 25 Number of studies = 21 Number of studies = 25 
Asian 433 56.8 ± 0.63 25.9% (21.1-31.4) 431 55.8 ± 1.02 1.6% (0.5-4.7) 432 56.7 ± 0.63 25.2% (20.5-30.7) 
Black  120 56.7 ± 0.58 51.1% (39.0-63.0) 65 57.0 ± 0.12  14.8% (5.6-33.7) 110 56.9 ± 0.54 58.0% (45.0-70.0) 
White 1,317 56.2 ± 0.46 57.3% (53.1-61.4) 1,100 56.5 ± 0.30 1.1% (0.4-2.5) 1,229 56.2 ± 0.46 61.1% (56.8-65.3) 
Other* 44 55.9 ± 0.49 74.1% (35.4-93.7) 42 -- -- 44 55.9 ± 0.48 74.1% (35.5-93.7) 
   P < 0.0001¥   P = 0.0025¥   P < 0.0001¥ 
TOTAL 1,914 56.3 ± 0.49 46.6% (43.7-49.4) 1,638 56.4 ± 0.46 1.6% (1.0-2.7) 1,815 56.3 ± 0.48 48.7% (45.9-51.6) 
Non-Oropharynx 
Number of studies = 21 Number of studies = 19 Number of studies = 21 
Asian 201 65.0 ± 0.50  27.1% (16.4-41.4) 200 64.6 ± 0.80 -- 200 64.1 ± 0.64 20.9% (11.9-34.0) 
Black  38 54.6 ± 0.22 13.3% (5.0-30.8) 20 55.5 ± 0.90 3.2% (0.4-22.6)** 21 54.9 ± 0.31 30.2% (12.9-55.7) 
White 806 59.2 ± 0.52 11.3% (8.7-14.6) 678 51.9 ± 0.76 1.5% (0.6-3.8)** 686 58.7 ± 0.59 17.2% (13.5-21.5) 
Other* 14 -- 6.7% (0.9-37.0) 12 -- 11.6% (1.3-56.3)** 14 -- 18.4% (4.2-53.3) 
   P = 0.0553¥   P = 0.1434¥   P = 0.6344¥ 
TOTAL 1,059 60.5 ± 0.55 13.4% (11.0-16.3) 910 59.9 ± 0.88 1.4% (0.6-3.2)** 921 60.1 ± 0.63 18.2% (15.2-21.8) 
*Other includes other race/ethnic groups and unknown race; †Adjusted for each study, year of diagnosis, square root age, gender, alcohol, and smoking status; **smoking status 
predicted HPV18 perfectly and was excluded as a covariate; ¥Chi-square p-value for the differences between the four race/ethnic group categories; SD = Standard Deviation; ϕAge at 
diagnosis was back transformed after ANOVA using square root transformation. 
Table 4: Predictors of overall survival (all-cause mortality) for oropharyngeal cancer patients according to 
smoking status and race 
All-cause mortality HR, 95% CI*   
Oropharynx 
All Races 
(N = 880) 
All Races 
Ever Smokers 
(n = 746) 
All Races 
Never Smokers 
(n = 134) 
White  
(n = 475) 
Non-White  
(n = 401) 
Stage 0/I/II 
(n = 149) 
Stage III/IV 
(n = 731) 
Race 
     White 
     Asian 
     Black 
     Other 
 
Age at diagnosis 
 
Smoking 
     Never smoker 
     Ever smoker 
 
Alcohol 
     Never drinker 
     Ever drinker 
 
Sex 
     Male 
     Female 
 
Stage 
    0/I/II 
    III/IV 
 
HPV/p16 status 
  HPV16,18+/p16+ 
  HPV16,18-/p16+ 
  HPV16,18+/p16- 
  HPV16,18-/p16- 
 
 
Ref (1.00) 
0.87 (0.56-1.37) 
0.85 (0.50-1.45) 
0.57 (0.08-4.15) 
 
1.25 (1.09-1.44) 
 
 
Ref (1.00) 
1.95 (1.34-2.83) 
 
 
Ref (1.00) 
1.00 (0.80-1.26) 
 
 
Ref (1.00) 
0.74 (0.54-1.01) 
 
 
Ref (1.00) 
2.08 (1.56-2.77) 
 
 
Ref (1.00) 
1.88 (1.19-2.97) 
3.24 (2.25-4.66) 
3.17 (2.39-4.20) 
 
Ref (1.00) 
0.80 (0.50-1.28) 
0.78 (0.45-1.37) 
-- 
 
1.23 (1.06-1.42) 
 
 
 
 
 
 
Ref (1.00) 
0.96 (0.76-1.22) 
 
 
Ref (1.00) 
0.74 (0.53-1.05) 
 
 
Ref (1.00) 
2.15 (1.59-2.90) 
 
 
Ref (1.00) 
1.82 (1.09-3.03) 
3.41 (2.32-5.01) 
3.30 (2.43-4.47) 
 
Ref (1.00) 
1.27 (0.27-5.91) 
2.14 (0.19-24.08) 
3.99 (0.46-34.18) 
 
1.47(0.90-2.39) 
 
 
 
 
 
 
Ref (1.00) 
1.45 (0.65-3.23) 
 
 
Ref (1.00) 
0.69 (0.30-1.61) 
 
 
Ref (1.00) 
1.83 (0.64-5.23) 
 
 
Ref (1.00) 
2.29 (0.74-7.08) 
2.19 (0.57-8.44) 
2.70 (1.12-6.51) 
 
 
 
 
 
 
1.75 (1.39-2.21) 
 
 
Ref (1.00) 
1.70 (0.99-2.93) 
 
 
Ref (1.00) 
1.46 (0.92-2.34) 
 
 
Ref (1.00)  
0.70 (0.49-1.01) 
 
 
Ref (1.00) 
2.20 (1.53-3.16) 
 
 
Ref (1.00) 
2.91 (1.72-4.92) 
3.30 (2.09-5.21) 
2.82 (1.94-4.10) 
 
 
 
 
 
 
1.00 (0.89-1.26) 
 
 
Ref (1.00) 
1.87 (1.11-3.17) 
 
 
Ref (1.00) 
0.89 (0.67-1.20) 
 
 
Ref (1.00) 
0.87 (0.48-1.59) 
 
 
Ref (1.00) 
2.13 (1.27-3.55) 
 
 
Ref (1.00) 
0.69 (0.24-2.01) 
2.95 (1.60-5.42) 
3.11 (1.97-4.92) 
 
Ref (1.00) 
2.54 (0.73-8.78) 
1.47 (0.27-7.82) 
-- 
 
1.45 (0.93-2.26) 
 
 
Ref (1.00) 
2.58 (0.79-8.46) 
 
 
Ref (1.00) 
1.06 (0.51-2.22) 
 
 
Ref (1.00) 
0.36 (0.16-0.81) 
 
 
 
 
 
 
Ref (1.00) 
7.96 (2.08-30.43) 
7.22 (2.26-23.11) 
4.36 (1.51-12.60) 
 
Ref (1.00) 
0.67 (0.41-1.11) 
0.71 (0.40-1.28) 
-- 
 
1.24 (1.07-1.43) 
 
 
Ref (1.00) 
2.08 (1.39-3.11) 
 
 
Ref (1.00) 
1.00 (0.79-1.28) 
 
 
Ref (1.00) 
0.87 (0.62-1.23) 
 
 
 
 
 
 
Ref (1.00) 
1.58 (0.95-2.63) 
2.85 (1.91-4.25) 
3.07 (2.28-4.13) 
*Covariates included: square root age, year of diagnosis, race, sex, smoking, alcohol, stage at diagnosis combined HPV16,18 and p16 status and study 
 
 
 
 Table 5: Risk of disease progression for oropharyngeal cancer patients according to HPV/p16 status and race  
 
Disease persistence and/or recurrence HR, 
95% CI* 
HPV/p16 status 
White 
N = 475 
Non-White 
N = 401 
 
HPV16,18+/p16+ 
HPV16,18-/p16+ 
HPV16,18+/p16- 
HPV16,18-/p16- 
 
Ref (1.00) 
2.33 (1.22-4.45) 
3.62 (2.21-5.95) 
3.23 (2.14-4.88) 
 
Ref (1.00) 
0.52 (0.12-2.27) 
1.44 (0.58-3.61) 
2.70 (1.52-4.82) 
 
Metastasis HR, 95% CI* 
HPV16,18+/p16+ 
HPV16,18-/p16+ 
HPV16,18+/p16- 
HPV16,18-/p16- 
Ref (1.00) 
1.84 (0.49-6.90) 
2.61 (0.90-7.51) 
2.08 (0.88-4.91) 
Ref (1.00) 
0.81 (0.35-1.88) 
1.08 (0.48-2.42) 
1.94 (1.26-2.99) 
*Adjusted for year of diagnosis, square root age, sex, race, stage, smoking, alcohol and study 
 
 
 
 
 
 
 
 
Figure Legends 
 
Figure 1: Flow diagram of study selection 
Figure 2: Proportions of combined HPV16,18 and p16 status among all (A), ever 
smoker (B) and never smoker (C) oropharynx cancer patients stratified by race   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Meta-Analysis of HPV Prevalence in Populations of African Descent, Stratified by Geographic 
Region and HPV Test Method 
Study 
HPV test 
Method HPV types detected N 
Any HPV 
N%, 95% CI 
HPV 16  
N%, 95% CI 
ALL HEAD AND NECK  
SUB-SAHARAN AFRICA      
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Ndiaye C et al. (2013)(50) PCR 16, 35, 45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
TOTAL    317 10.7% (1.0-27.2) 1.0% (0.0-3.9) 
p value, Q test    0.000 0.129 
I2 test    92.0% 47.0% 
p value, Egger’s test    0.600 0.686 
      
PCR methods only      
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Ndiaye C et al. (2013)(50) PCR 16, 35, 45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
TOTAL    251 16.2% (2.3-37.7) 1.7% (0.0-5.4) 
p value, Q test    0.000 0.184 
I2 test    91.9% 40.9% 
USA      
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Argwal et al. (2008)(43) ISH 16 13 0.0% (0.0-24.7)  0.0% (0.0-24.7) 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    798 21.7% (13.7-30.8) 25.0% (12.3-40.2) 
p value, Q test    0.000 0.000 
I2 test    74.3% 89.0% 
p value, Egger’s test    0.249 0.967 
      
PCR methods only      
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL     26% (17.7-35.3) 29.4% (15.8-45.0) 
p value, Q test    0.002 0.000 
I2 test    71.1% 89.0% 
OROPHARYNX 
USA      
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013) (49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    146 31.5% (17.7-47.1) 45.7% (25.5-66.6) 
p value, Q test    0.003 0.000 
I2 test    75.5% 84.1% 
p value, Egger’s test    0.997 0.807 
      
PCR methods only      
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013) (49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    182 36.9% (22.8-52.1) 45.7% (25.5-66.6) 
p value, Q test    0.025 0.000 
I2 test    68% 84.1% 
NON-OROPHARYNX 
SUB-SAHARAN AFRICA      
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
TOTAL    212 12.2% (0.0-38.1) 0.1% (0.0-1.8) 
p value, Q test    0.000 0.768 
I2 test    93.9% 0.0% 
p value, Egger’s test    0.280 0.881 
      
PCR methods only      
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
TOTAL    146 20.8% (0.0-62.3) 0.3% (0.0-2.9) 
p value, Q test    0.000 0.932 
I2 test    94.4% 0.0% 
USA      
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 125 24.8% (17.5-33.3)  
Isayeva et al. (2015)(52)* qRT-PCR 16,18 22  13.6% (2.9-34.9) 
TOTAL    337   
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Adjusted prevalence of HPV16 and HPV18 according to race stratified by head and neck 
sub-site with regression coefficients and standard errors. 
 
HPV16 
 
HPV18 
 
HPV16,18 
Coefficient Standard Error  Prevalence† Coefficient Standard Error Prevalence† Coefficient Standard Error Prevalence† 
All HNC 
Number of studies = 28 Number of studies = 24 Number of studies =28 
Asian -0.391 0.148 28.4% (23.8-33.4)  0.021 0.598 1.6% (0.7-3.9)  -0.808 0.155 26.0% (21.6-30.9) 
Black  0.283 0.219 43.7% (34.2-53.8)  1.902 0.532 9.8% (4.0-21.9)  0.490 0.241 56.2% (45.1-66.7) 
White (reference) -- 36.9% (34.0-40.0)  (reference) -- 1.6% (0.9-2.8)  (reference) -- 44.0% (40.8-47.3) 
Other* -0.117 0.511 34.3% (16.2-58.5)  1.644 1.084 7.7% (1.0-39.6)    0.033 0.513 44.9% (23.1-68.8) 
   P=0.0123¥    P = 0.0077¥    P < 0.0001¥ 
TOTAL   35.0% (32.8-37.2)    1.9% (1.2-2.8)    39.3% (37.1-41.7) 
Oropharynx 
Number of studies = 25 Number of studies = 21 Number of studies = 25 
Asian -1.344 0.182 25.9% (21.1-31.4)  0.372 0.828 1.6% (0.5-4.7)  -1.540 0.189 25.2% (20.5-30.7) 
Black  -0.252 0.271 51.1% (39.0-63.0)  2.769 0.682 14.8% (5.6-33.7)  -0.129 0.290 58.0% (45.0-70.0) 
White (reference) -- 57.3% (53.1-61.4)  (reference) -- 1.1% (0.4-2.5)  (reference) -- 61.1% (56.8-65.3) 
Other* 0.758 0.846 74.1% (35.4-93.7)  -- -- --  0.598 0.845 74.1% (35.5-93.7) 
   P < 0.0001¥    P = 0.0025¥    P < 0.0001¥ 
TOTAL   46.6% (43.7-49.4)    1.6% (1.0-2.7)    48.7% (45.9-51.6) 
Non-Oropharynx 
Number of studies = 21 Number of studies = 19 Number of studies = 21 
Asian 1.069 0.397 27.1% (16.4-41.4)    --  0.241 0.401 20.9% (11.9-34.0) 
Black  0.183 0.571 13.3% (5.0-30.8)  0.784 1.133 3.2% (0.4-22.6)**  0.735 0.568 30.2% (12.9-55.7) 
White (reference) -- 11.3% (8.7-14.6)  (reference) -- 1.5% (0.6-3.8)**  (reference) -- 17.2% (13.5-21.5) 
Other* -0.569 1.073 6.7% (0.9-37.0)  2.155 1.209 11.6% (1.3-56.3)**  0.083 0.834 18.4% (4.2-53.3) 
   P = 0.0553¥    P = 0.1434¥    P = 0.6344¥ 
TOTAL   13.4% (11.0-16.3)    1.4% (0.6-3.2)**    18.2% (15.2-21.8) 
*Other includes other race/ethnic groups and unknown race; †Adjusted for each study, year of diagnosis, square root age, gender, alcohol, and smoking status; **smoking status 
predicted HPV18 perfectly and was excluded as a covariate; ¥Chi-square p-value for the differences between the four race/ethnic group categorie 
